Rhythm Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Rhythm Pharmaceuticals Inc share price today is $88.01, up -3.17%. The stock opened at $96.71 against the previous close of $90.31, with an intraday high of $99.64 and low of $86.745.

Rhythm Pharmaceuticals Inc Share Price Chart

Rhythm Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock

Rhythm Pharmaceuticals Inc Share Price Performance

$88.01 -0.0317(-3.17%) RYTM at 23 Mar 2026 03:06 PM Biotechnology
Lowest Today 86.745
Highest Today 99.64
Today’s Open 96.71
Prev. Close 90.31
52 Week High 122.20
52 Week Low 45.91
Day’s Range: Low 86.745 High 99.64
52-Week Range: Low 45.91 High 122.20
1 day return -
1 Week return -3.39
1 month return -9.12
3 month return -22.62
6 month return -11.84
1 year return +62.7
3 year return +417.09
5 year return +243.98
10 year return -

Rhythm Pharmaceuticals Inc Institutional Holdings

RA Capital Management, LLC 9.76

BlackRock Inc 9.23

Vanguard Group Inc 9.10

Baker Bros Advisors LP 8.21

PRIMECAP Management Company 5.09

NEA Management Company, LLC 4.26

JPMorgan Chase & Co 3.48

PRIMECAP Odyssey Aggressive Growth 3.16

Vanguard Total Stock Mkt Idx Inv 3.09

State Street Corp 2.97

The Goldman Sachs Group Inc 2.77

Federated Hermes Inc 2.53

FMR Inc 2.50

Vanguard Small Cap Index 2.21

T. Rowe Price Associates, Inc. 2.05

Geode Capital Management, LLC 2.01

iShares Russell 2000 ETF 1.88

Driehaus Capital Management LLC 1.88

Westfield Capital Management Company, L.P. 1.86

Polar Capital Holdings PLC 1.74

HHG PLC 1.70

PRIMECAP Odyssey Growth 1.66

Polar Capital Biotech S Inc 1.46

Checkpoint Capital LP 1.45

American Funds SMALLCAP World A 1.45

Capital Research Global Investors 1.44

State Street® SPDR® S&P® Biotech ETF 1.36

Vanguard Small Cap Growth Index Inv 1.23

Federated Hermes Kaufmann Growth 1.04

Federated Hermes Kaufmann R 1.04

Federated Hermes Kaufmann Small Cap A 0.99

Federated Hermes Kaufmann Small Cap Grow 0.99

Vanguard Institutional Extnd Mkt Idx Tr 0.96

BGF World Healthscience A2 0.82

BlackRock Health Sciences Opps Inv A 0.79

Fidelity Small Cap Index 0.76

ACAP Strategic A 0.74

JPM US Mid Cap Growth-Composite 0.70

JPMorgan Mid Cap Growth I 0.70

Perceptive Advisors LLC 0.00

Rhythm Pharmaceuticals Inc Market Status

Strong Buy: 8

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Rhythm Pharmaceuticals Inc Fundamentals

Market Cap 5971.53 M

PB Ratio 42.9393

PE Ratio 0.0

Enterprise Value 5717.53 M

Total Assets 481.19 M

Volume 3232819

Rhythm Pharmaceuticals Inc Company Financials

Annual Revenue FY23:61984000 62.0M, FY22:23638000 23.6M, FY21:3154000 3.2M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:54887000 54.9M, FY22:21505000 21.5M, FY21:2555000 2.6M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-185538000 -185.5M, FY22:-183081000 -183.1M, FY21:-68007000 -68.0M, FY20:-130727000 -130.7M, FY19:-134624000 -134.6M

Quarterly Revenue Q3/2025:51298000 51.3M, Q2/2025:48502000 48.5M, Q1/2025:32704000 32.7M, Q3/2024:33251000 33.3M, Q2/2024:29078000 29.1M

Quarterly Profit Q3/2025:45799000 45.8M, Q2/2025:42959000 43.0M, Q1/2025:29056000 29.1M, Q3/2024:29423000 29.4M, Q2/2024:25954000 26.0M

Quarterly Net worth Q3/2025:-52904000 -52.9M, Q2/2025:-46632000 -46.6M, Q1/2025:-49498000 -49.5M, Q3/2024:-44970000 -45.0M, Q2/2024:-32261000 -32.3M

About Rhythm Pharmaceuticals Inc & investment objective

Company Information Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 414

Industry Biotechnology

CEO Dr. David P. Meeker M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Rhythm Pharmaceuticals Inc FAQs

What is the share price of Rhythm Pharmaceuticals Inc today?

The current share price of Rhythm Pharmaceuticals Inc is $88.01.

Can I buy Rhythm Pharmaceuticals Inc shares in India?

Yes, Indian investors can buy Rhythm Pharmaceuticals Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Rhythm Pharmaceuticals Inc shares in India?

You can easily invest in Rhythm Pharmaceuticals Inc shares from India by:

Can I buy fractional shares of Rhythm Pharmaceuticals Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Rhythm Pharmaceuticals Inc?

Rhythm Pharmaceuticals Inc has a market cap of $5971.53 M.

In which sector does Rhythm Pharmaceuticals Inc belong?

Rhythm Pharmaceuticals Inc operates in the Biotechnology sector.

What documents are required to invest in Rhythm Pharmaceuticals Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Rhythm Pharmaceuticals Inc?

The PE ratio of Rhythm Pharmaceuticals Inc is N/A and the PB ratio is 42.94.